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INTRODUCTION 
The oral cavity is an attractive site for drug delivery due 
toease of administration, avoidance of possible 
drugdegradation in the gastrointestinal tract and first-
passmetabolism. Buccal delivery system involves 
theadministration of the desired drug through the buccal 
mucosal membrane lining of the oral cavity. 
Prolongedrelease of the drug and increased 
bioavailability leads to thesignificant reduction in the 
dose and dose related side effects. Moreover buccal 
drug absorption can be promptly terminatedin case of 
toxicity by removing the dosage from the buccal cavity 
therefore mucoadhesive dosage forms were 
suggestedfor oral drug delivery which includes various 
mucoadhesive devices such as patches, tablets, films, 
gels, disc, and strips andointment
1
. 
Mucoadhesion is defined as the interaction between a 
mucin surface and a synthetic or natural polymer. 
Mucoadhesion can also be explained as the ability of 
synthetic orbiological macromolecules to adhere to 
mucosal tissues. Mucoadhesive controlled release 
devicescan improve the effectiveness of the 
drugconcentration between minimum 
effectiveconcentration and maximum safeconcentration. 
Also they inhibit the dilutionof drug in the body fluids 
and allowtargeting and localization of a drug atspecific 
site. Mucoadhesive also increases the intimacy and 
duration of contactbetween a drug containing polymer 
andmucous surface. The combined effect ofthe direct 
drug absorption and decrease inexcretion rate (due to 
prolonged residencetime) causes an increased 
bioavailabilityof the drug with smaller doses and 
lessfrequent administration. Drugs that areabsorbed 
through the mucosal lining oftissues can enter directly 
into the bloodstream so that these drugs are 
preventedfrom enzymatic degradation in the GIT
2
.
 
Buccal delivery of drugs provides an attractive 
alternative to the oral route of drug administration, 
particularly in overcoming deficiencies associated with 
the latter mode of dosing. Problems such as First pass 
metabolism and drug degradation in the GIT 
environment can be circumvented by administering the 
drug via buccal route. Moreover, the oral cavity is 
easily accessible for self-medication. The advantages of 
buccal drug delivery include: low enzymatic activity, 
painless drug administration, easy drug withdrawal
3
. 
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ABSTRACT 
Candesartan is  an  angiotensin  II  receptor antagonist  and  is  widely  used  in  the  management  of  hypertension  to  reduce  
cardiovascular mortality  in patients with left  ventricular  dysfunction  following  myocardial  infarction,  and  in  the  
management  of  heart  failure. The Mucoadhesive buccal tablets were prepared by direct compression method using carbopol 
934, HPMC K4M, sodium CMC as mucoadhesive polymer. The compatibility studies of drug and excipients were performed 
by FT-IR spectroscopy. After examining the flow properties of the powder blends the results are found to be within prescribed 
limits and indicated good flowing property, hence it was subjected to tablet compression. The tablets were evaluated for post-
compression parameters like weight variation, hardness, thickness, friability, drug content uniformity, Surface pH, in-vitro 
studies like swelling, mucoadhesive strength and drug release. Formulation (F6) containing Carbopol-934 and Sodium CMC in 
the ratio of (2: 3) showed good mucoadhesive strength (36.14) and maximum drug release of 98.15% in 8 hrs. Swelling 
increases with increase in concentration of Sodium CMC in tablets. The drug content of shown highest of 99.15 %, Surface pH 
was found to be 6.42. All the evaluation parameters given the positive results and comply with the standards. Stability studies 
were carried out on the developed formulations indicated that the formulations were stable during the study period. The results 
indicate that the mucoadhesive buccal tablets of Candesartan may be good choice to bypass the extensive hepatic first pass 
metabolism with an improvement in the bioavailability of candesartan through buccal mucosa. 
Key Words: Mucoadhesive buccal tablets, direct compression, Hypertension, Candesartan cilexetil, 
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Candesartan cilexetil belongs to the class of angiotensin 
receptor antagonist and acts by bindingselectively and 
non-competitively to angiotensin II receptor type 1, thus 
preventing actions ofangiotensin II. The drug finds most 
significant clinical uses in the treatment of hypertension 
ofall grades. Candesartan cilexetil is an ester prodrug of 
its active metabolite Candesartan, to whichit owes its 
therapeutic effect. Candesartan cilexetil is white to off-
white crystalline powder having melting point of 157-
160°C, and is water insoluble. Candesartan acts by 
inhibits the binding of angiotensin II to theAT1-
Receptor. Candesartan cilexetil is hydrolyzed to 
candesartan during absorption fromgastrointestinal 
tract. It is used in themanagement of hypertension and 
may also be used inheart failure in patients with 
impaired left ventricular systolic function, either when 
ACEinhibitors are not tolerated, or in addition to ACE 
inhibitors. Candesartan cilexetil is widely used for the 
treatment of hypertension and heart failure in clinical 
application. It is available in 4 mg, 8 mg, 16 mg, 32 mg 
and can be used in the dose range of8-32 mg/day
4
. 
Hence, the aim of present work is to develop a 
formulation and evaluation of mucoadhesivebuccal 
tablets of Candesartan. 
MATERIALS AND METHODS 
Materials:   
Candesartan cilexetil was obtained as gift sample from 
Micro labs, Bengaluru, India. Carbopol 934, HPMC 
K4M, Sodium CMC, Sodium alginate, Menthol, Talc, 
Lactose, Saccharin sodium were obtained from S.D fine 
chemicals limited, Mumbai, India. Magnesium stearate 
wasobtained from Leo chem,S.puram, Bengaluru.  
Methods: 
The compatibility studies of drug and excipients were 
determined by FTIR studies. Both pure drug and 
excipients were individually analysed and further the 
physical mixture and formulations were also studied. 
Preparation of Mucoadhesivebuccal tablets of 
Candesartan cilexetil by direct compression method: 
Mucoadhesive buccal tablets of Candesartan cilexetil 
were prepared by direct compression method by using 
as carbopol 934,HPMC K4M, sodium CMC as 
mucoadhesive polymers. MCC as filler, saccharin 
sodium as sweetening agents, lactose as diluents, 
magnesium stearate as lubricant, talc used as glidants. 
Before going to direct compression all the ingredients 
were screened through sieve no.100, except lubricant all 
the ingredients were thoroughly blended in a glass 
mortar with pestle for15 min. After sufficient mixing 
lubricant was added and again mixed for additional 2-3 
min.Before compression, hardness was adjusted and 
compressed into 150mg each tablets using tablet 
compression machine equipped with 5mm flat faced 
bevelled edge punches on 12 station rotary tablet 
machine and same hardness was used for the required 
number tablets. The various formulations designed were 
shown in Table 1
5
. 
 
Table 1: Formulation development of Mucoadhesivebuccaltablet of Candesartan 
 
 
 
 
 
 
 
 
 
Pre-Compression Parameters
 
Pre-compression parameters. The various Pre-
compression parameters like Angle of repose, Bulk 
density, Tapped density, compressibility index, 
Hausner‟s ratio and Carr‟s index were studied6,7. 
Angle of Repose:: The angle of repose of granules was 
determined by the funnel method. The accurately 
weighed granules were taken in a funnel. The height of 
the funnel was adjusted in such a way that the tip of the 
funnel just touched the apex of the heap of the 
granules. The granules were allowed to flow through 
the funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was 
calculated using the following equation       
Tan θ = h/r 
Where h and r are the height and radius of the powder 
cone. 
Bulk Density (Db): It is the ratio of total mass of 
powder to the bulk volume of powder. It was measured 
by pouring the weighed powder into a measuring 
cylinder and the volume was noted. It is expressed in 
gm/ml and is given by                       
 Db= Mass powder/Volume 
Tapped density (Dt ): It is the ratio of total mass of 
powder to the tapped volume of powder. The tapped 
volume was measured by tapping the powder to 
constant volume. It is expressed in gram/ml and is 
given by                                          
Dt =M/Vt 
INGREDIENTS (mg) F1 F2 F3 F4 F5 F6 
Candesartan cilexetil 4 4 4 4 4 4 
Carbopol 934 15 15 15 15 15 15 
HPMC K4M 15 20 25 - - - 
Sodium CMC - - - 15 20 25 
MCC 80 75 70 80 75 70 
Magnesium stearate 4 4 4 4 4 4 
Talc 4 4 4 4 4 4 
Lacose 18 18 18 18 18 18 
Saccharin sodium 10 10 10 10 10 10 
Total weight 150 150 150 150 150 150 
Vinay et al                                        Journal of Drug Delivery & Therapeutics. 2015; 5(5):56-63 58 
© 2011-15, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Where, M - Mass of the powder             
V t – Tapped volume of the powder. 
Compressibility index (I) and Hausner‟s ratio: Carr‟s 
index and Hausner‟s ratio measure the propensity of 
granule to be compressed and the flow ability of 
granule. Carr‟s index and Hausner‟s ratio were 
calculated using following formula.                                
C.I =(Dt – Db)100/Dt          
Where,        Dt – Tapped density of the powder                    
Db – Bulk density of the powder 
Post-Compression Parameters 
The Candesartan cilexetil tablets prepared were 
evaluated for the following various post compression 
parameters:  
Organoleptic Characters 
Organoleptic characters properties such as colour, 
odour, taste, were evaluated for tablets from each batch 
were randomly selected and taste tested, colour 
visually compared and odour checked.
 
Weight variation  
The weight of the tablet being made was routinely 
determined to ensure that a tablet contains the proper 
amount of drug. The weight variation test is done by 
selecting 20 tablets randomly from each formulation 
after compression, weighed individually using a 
“Electronic weighing balance” and average weight was 
determined. The individual weights are compared with 
the average weight for the determination weight 
variation6. 
Tablet hardness  
The resistance of tablets to shipping or breakage under 
conditions of storage, transportation and handling 
before usage depends on its hardness. The hardness of 
each batch of tablet was checked by using “Monsanto 
hardness tester”. The hardness was measured in terms 
of kg/cm2. 
Friability  
Friability generally refers to loss in weight of tablets in 
the containers due to removal of fines from the tablet 
surface. Friability generally reflects poor cohesion of 
tablet ingredients. The friability was determined by 
using roche friabilator7. 
Tablet thickness  
Thickness of the tablet is important for uniformity of 
tablet size. Thickness was measured using “Vernier 
Callipers”. It was determined by checking the 
thickness of ten tablets of each formulation7. 
Drug content uniformity 
The tablets were tested for their drug content 
uniformity. At randomly selected 6 tablets from each 
formulation were finely powdered and dissolved in 
100ml of phosphate buffer solution at pH 6.8. The 
solution was shaken thoroughly and the concentration 
of drug was determined spectrophotometrically by 
using SHIMADZU UV 1800 at 277nm7. 
Surface pH  
The surface pH of the buccal tablets was determined 
Battenberg method in order to investigate the 
possibility of any in-vivo side effects likean acidic or 
alkaline pH may cause irritation to the buccal mucosa. 
A combined glass electrode was used for this purpose. 
The tablets were allowed to swell by keeping it in 
contact with distilled water (pH 6.5 ± 0.05) for 2 hrs at 
room temperature. The pH was measured by bringing 
the electrode in contact with the surface of the tablet 
and allowing it to equilibrate for 1 min(Table 4 )
8
.   
In- vitro swelling studies  
The degree of swelling of bio-adhesive polymers is an 
important factor affecting adhesive strength. For 
conducting the study, a tablet was weighed and placed 
in a petridish containing 5 ml of phosphate buffer at 
pH 6.8 for 12 hrs, the tablets were taken out from the 
petridish and excess water was removed carefully by 
using filter paper. The swelling Index was calculated 
using the following formula and results are 
summarized in Table 5.   
Swelling Index (SI) + (Wt-Wo)/Wo X 100  
Where 
 SI= Swelling index.           
Wt = Weight of tablets after time at„t‟             
Wo = Weight of tablet before placing in the beaker
8 
In-vitro mucoadhesive Study  
Mucoadhesive strength of the tablets was measured on 
a modified two-arm physical balance. The sheep 
buccal mucosa was used as biological membrane for 
the studies. The sheep mucosa was obtained from the 
local slaughter house and stored in krebs buffer at 4
0
C 
from the time of collection and used within 3 hrs of 
procurement. The membrane was washed with distilled 
water and then with phosphate buffer pH 6.8 at 37
0
C. 
The buccal mucosa was cut into pieces and washed 
with phosphate buffer pH 6.8. A piece of buccal 
mucosa was tied to the glass vial, which was filled 
with phosphate buffer. The glass vial was tightly fitted 
into a glass beaker (filled with phosphate buffer pH 6.8 
at 37
0
 C ± 0.5
0
C), so that it just touches the mucosal 
surface. The buccal tablets were suck to lower side of a 
rubber stopper. The two side of the balance were made 
equal before the study, by keeping a 5 gms, was 
removed from the right-hand pan, which lowered the 
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pan along with the tablet over the mucosa. The balance 
was kept in the position for 1 min contact time. 
Mucoadhesive strength was assessed in terms of 
weight (gm) required to detach the tablet from the 
membrane. Mucoadhesive strength which was 
measured as force of adhesion in Newton‟s (Table 8) 
by using following formula
8
. 
Force of adhesion (N) = Mucoadhesive strength / 100 
× 9.81 
In-vitroDissolution studies
 
Dissolution testing was carried out with “Paddle type-
II USP dissolution test apparatus” at rpm 50 and 
temperature 37±0.5°C both dissolution media and 
water. At each specified intervals of time 5 ml sample 
was withdrawn and replaced by fresh media. The 
samples were analytically tested to determine the 
concentration by UV spectroscopy method at 
wavelength of 277 nm. The % drug release was 
calculated using an equation obtained from the 
calibration curve
4
. 
Details of Dissolution Test: 
 
Dissolution test apparatus     : USP type II 
Speed                                    : 50 rpm 
Stirrer                                   : Paddle type 
Volume of medium                : 900 ml 
Volume withdrawn                 : 5 ml 
Medium used                        : phosphate buffer 
p
H
 6.8 
Temperature                            : 37±0.5ºC 
λmax    :277nm 
Further The cumulative amount drug released from the 
formulations at different time intervals were subjected 
to various kinetic models such as zero order, first 
order, higuchi and korsmeyer-peppas model to 
characterize mechanism of drug release. 
Stability Studies
 
Stability can be defined as the capacity of drug product 
to remain within specifications established to ensure its 
identity, strength, quality, and purity.The formulations 
were subjected to short term stability studies. The 
formulations were packed in aluminium foil in tightly 
closed container. They were then stored at 30ºC 65% 
RH and 40ºC / 75% RH for two months and evaluated 
for their post-compression studies. 
RESULTS AND DISCUSSION 
The compatibility studies revealed both drugs and 
excipients were compatible after FT IR studies, the 
results shown in Figure 1. 
 
Pre-compression evaluation parameters 
For each type of formulation blends of active 
pharmaceutical ingredients and excipients were 
prepared and evaluated for various parameters as 
explained earlier. Bulk density was found in the range 
of 0.496-0.0.576 g/cm
3
 and the tapped density between 
0.560 - 0.108 g/cm
3
. Using the above two density data, 
Carr‟s compressibility index were calculated. The 
compressibility index was found between 14.23-
17.24% and the compressibility and flow ability data 
indicated good flow properties of all powder blends. 
The better flow property of all powder blends was also 
evident from angle of repose. The angle of repose was 
range of 27.21
°
-29.56°. Angle of repose below 30º 
indicates good flow property. In the present study all 
powder blends showed good flow property. The results 
are shown in Table 2. 
 
 
Table 2: Pre-compression parameters 
 
 
 
 
 
 
 
Code Bulk density g/cm
3
 Tapped density 
g/cm
3
 
Carr’s index% Hausner’s 
ratio 
Angleofrepose(°) 
F1 0.576±0.094 0.630±0.120 16.84±0.03 1.20 29.56±0.04 
F2 0.530±0.101 0.626±0.034 15.49±0.094 1.18 28.19±0.067 
F3 0.528±0.074 0.630±0.069 14.63±0.065  1.17 27.89±0.051 
F4 0.523±0.089 0.632±0.091 17.24±0.074 1.20 27.21±0.079 
F5 0.561±0.093 0.623±0.113 16.37±0.093 1.19 27.97±0.084 
F6 0.496±0.112 0.560±0.108 14.23±0.034 1.18 27.61±0.099 
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A: Pure Drug Candesartan cilexetil 
 
B: Drug with HPMC K4M 
 
C: Formulation F5 
Figure 1: FTIR studies of pure drug, with excipients and formulation 
 
Post- Compression evaluation parameters 
Organoleptic characters: 
Various organoleptic properties viz. taste, colour and 
odour performed on all the formulations, the results 
found that all the formulations were sweet in taste, 
white in colour and odour less. 
Thickness  
Thickness of all the formulations was evaluated as per 
the procedure and the average values was ranges 
between minimum of 2.12mm to maximum of 2.32mm 
and found to be within the allowed limit of deviation 
i.e. 5% of the standard value. Also the crown diameter 
of all the formulation was 6 mm and the results are 
shown in Table 3. 
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Table 3:Post- compressionparameter 
 
 
 
 
 
 
 
 
 
 
 
Hardness  
All the tablet formulations were evaluated for their 
hardness as per procedure and the results were shown in 
Table 3. All the formulations have an average hardness 
in between 4.20 to 4.30 kg/cm2 which was found to be 
acceptable. 
Friability 
All the Mucoadhesive buccal tablets were evaluated for 
their percentage friability as per the procedure and the 
results are shown in Table 3. The average percentage 
friability for all the formulations were found between 
0.39% to 0.56%, which is observed to be within the 
limit as per the standard (i.e. maximum 1%).  
Weight Variation      
All the formulations were evaluated for their uniformity 
of weight according to the procedure and the results 
were shown in Table 3. The maximum weight of 152.20 
mg for F3 and the minimum weight of 148.10 mg for 
F2 formulations were observed. The maximum allowed 
percentage weight variation for tablets 150 mg by 
Indian pharmacopoeia is 7.5%, and no formulations 
were exceeded the limit. Thus all the formulations were 
found to be complying with the standards given in IP. 
Drug Content 
All the formulations were evaluated for their uniformity 
of drug content according to the procedure and data 
were shown in Table 3. The percentage drug content of 
all formulations was found in the range of 95.00 to 
99.15% w/w.  The maximum drug content of 99.15% 
w/w for F6 and the minimum of 95.00% w/w for F2 
formulations was observed. 
Surface pH 
The surface pH of tablets of each formulation (F1 to F6) 
was tested and the results are provided in Table 4. The 
maximum and minimum pH values of the formulations 
were found to be 6.42 and 5.22 respectively. The 
acceptable pH of saliva is in the range of 5-7 and the 
surface pH of all tablets is within limits. Hence, the 
formulations may not produce any irritation to the 
buccal mucosa. 
 
Table 4: Surface pH, Mucoadhesive strength, Mucoadhesive force 
Code Surface pH Mucoadhesive 
strength(G) 
Mucoadhesive force 
(N) 
F1 5.22 30.20 2.90 
F2 5.60 32.14 3.19 
F3 6.34 34.18 3.17 
F4 6.10 29.14 3.52 
F5 6.14 32.17 2.94 
F6 6.42 36.14 2.80 
 
In-vitro drug release studies 
The drug release pattern was studied for all 
formulations (F1 to F6) for 10 hours and the profile is 
shown in Figure 2. The most important factor affecting 
the rate of release from buccal tablet is the drug, type of 
polymer and polymer ratio. The percentage cumulative 
drug release profile from formulations F1, F2, F3, 
F4,F5 and F6  at 8hrs showed 82.10%, 85.13%, 
88.14%, 93.16%, 94.17% and 98.13% drug release 
respectively. It was concluded that by increasing the 
concentration of carbopol934 in the formulations (F1 to 
F6), the drug release rate from the tablet was found to 
be decreased, but when the concentration of secondary 
polymers HPMC K4M and Sodium CMC is increase, 
the drug release rate was found to be increased. This 
may be attributed to increased hydration followed by 
increased swelling of polymers with increase in 
concentration.The release data was fitted to various 
mathematical models such as zero order, first order, 
Higuchi, Korsmeyer-peppas and it was found that the 
drug release follows first order kinetics. 
 
 
 
 
Code Weight 
variation (mg) 
Hardness 
(kg/cm
2
) 
Thickness 
(mm) 
Friability 
(%) 
Drug content 
(%) 
F1 149.21±0.22 4.25±0.10 2.12±0.01 0.39±0.15 98.51±0.57 
F2 148.10±0.22 4.30±0.09 2.15±0.03 0.56±0.11 95.00±0.42 
F3 152.20±0.49 4.30±0.04 2.18±0.03 0.40±0.09 97.85±0.32 
F4 150.10±0.41 4.30±0.07 2.12±0.02 0.43±0.62 98.79±0.27 
F5 148.50±0.32 4.20±0.05 2.32±0.01 0.42±0.44 97.01±0.89 
F6 149.30±0.91 4.25±0.03 2.19±0.04 0.50±0.53 99.15±0.42 
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Figure 2: In-vitro drug release studies  
 
Table 5: In-vitro Swelling study of Candesartan cilexetil 
 
Code 
Percentage hydration 
1hr 2hr 4hr 8hr 
F1 30.11 38.12 28.12 70.12 
F2 35.15 48.15 35.16 78.13 
F3 38.12 55.18 45.12 85.14 
F4 45.12 62.17 60.13 88.12 
F5 50.13 66.13 71.12 87.18 
F6 48.23 58.12 80.13 90.12 
 
Stability studies results  
The formulations subjected to the stability studies and 
the evaluation parameters performed after the study 
period was shown no significant changes with respect to 
the initial observations. Further the results were 
compared and all the formulations found to be stable 
during the study period. 
CONCLUSIONS  
The Mucoadhesive buccal tablets were prepared by 
direct compression method using carbopol 934, HPMC 
K4M, sodium CMC as mucoadhesive polymer. A total 
of six formulations were prepared. The powder 
properties like angle of repose, bulk density, tapped 
density; Hausner‟s ratio and Carr‟s index of all the 
formulations were found to be within the standard 
limits. All the post-compression characteristics of the 
formulations like thickness, weight variation, hardness, 
friability, drug content and surface pH, in-vitro studies 
like swelling, mucoadhesive strength and drug release 
were found to be well within the limits of official 
standards. The overall studies indicated that the 
polymers Carbopol 934and Sodium CMC in the ratio of 
2 : 3 showed satisfactory mucoadhesive properties. 
Among the 6 formulations, the formulation F6 using 
these polymers in the above ratio with drug exhibited 
significant swelling properties with optimum release 
profile. Hence it can be concluded that the formulation 
F6 will be useful for buccal administration for the 
treatment of anti-hypertensive drug. Hence the 
mucoadhesive buccal tablets of Candesartan may be a 
good choice to bypass the extensive hepatic first pass 
metabolism with an improvement in the bioavailability 
through Buccal mucosa. The release data was showed 
that the drug release follows first order 
kinetics.Stabilitystudies showed there were significant 
changes in the parameters even after the period of 60 
days. From these results it was concluded that, the 
candesartan is suitable to develop in to Mucoadhesive 
buccal tablets, further clinical trials and commercial 
exploitation is needed for the better usefulness in the 
intended therapeutic treatment. 
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